Three medications are FDA-approved to treat alcohol dependence: naltrexone (a daily tablet or a monthly injection), acamprosate, and disulfiram. They lower cravings, blunt alcohol’s rewarding effect, or make drinking physically unpleasant, and they work best paired with counseling, which is how we build alcohol use disorder treatment across Colorado and New Mexico.
Here at Porch Light Health, we know that asking about these medications is rarely a casual question.
Naltrexone, acamprosate, and disulfiram are the three FDA-approved medications for alcohol dependence, and each works as a pill that helps stop drinking in a different way. Oral naltrexone and acamprosate carry the strongest evidence, medication works best alongside counseling, and a few baseline labs are all it usually takes to start safely.
Medication for alcohol use disorder, sometimes shortened to MAUD, refers to prescription drugs that reduce cravings, blunt alcohol’s rewarding effect, or create an unpleasant reaction to drinking. It sits inside the broader category of medications for addiction treatment (MAT), the same clinical model used for opioid use disorder.
Medication is one part of care, not a substitute for the rest of it.
A note on wording: the FDA labels for these drugs were written before the current diagnostic manual and use the older term “alcohol dependence” rather than “alcohol use disorder.” The conditions overlap, and clinicians use the newer term in practice.
Very few people who could benefit actually get these medications.
Figures from the National Institute on Alcohol Abuse and Alcoholism, drawing on 2024 National Survey on Drug Use and Health data, show that an estimated 27.1 million U.S. adults had alcohol use disorder in the past year in 2024.
About 2.0 million of them (7.5%) received any alcohol use treatment, and only 2.4%, roughly 665,000 people, received medication for it. Closing that gap is what our network is built to do.
Alcohol use disorder is a medical diagnosis, not a judgment call. A clinician looks at 11 criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, covering things like drinking more than you meant to, unsuccessful attempts to cut back, cravings, tolerance, withdrawal, and drinking that interferes with work or school.
The number of criteria you meet in a 12-month period sets the severity:
| Severity | Criteria Met | What It Often Means for Medication |
| Mild | 2 to 3 | Medication may be offered, often alongside brief counseling |
| Moderate | 4 to 5 | Medication is commonly recommended |
| Severe | 6 or more | Medication is strongly recommended per major guidelines |
Meeting two criteria is enough for a diagnosis. Many people are surprised to learn they qualify, and many are relieved to learn that alcohol addiction is a treatable medical condition with real medications behind it.
Most care starts with a short screen rather than a full assessment. The AUDIT-C is a three-question tool scored from 0 to 12 that takes a minute or two and asks how often you drink, how much you typically drink, and how often you have a heavy-drinking occasion.
A score of 4 or higher in men and 3 or higher in women counts as a positive screen, according to the National Institute on Drug Abuse, meaning a fuller conversation is worthwhile. A positive screen is not a diagnosis.
The Department of Veterans Affairs and Department of Defense use a higher cutoff of 5 or more, which matters if you are getting care through the VA system.
Adults with moderate to severe alcohol use disorder who want to cut back or stop drinking are the clearest candidates, and medication is also offered for mild cases. Both major U.S. guidelines support offering pharmacotherapy to people who do not have contraindications.
Medication tends to help most when:
The goal is rarely to “cure” alcohol use disorder. The disulfiram label says it plainly: the medication “is not a cure for alcoholism.” Realistic goals include:
Three things these medications are not:
Three molecules are approved, delivered as four products:
Each targets a different biological pathway, which is why matching the medication to your goals matters more than picking a “best” drug.
The current evidence standard is a 2023 systematic review and meta-analysis published in JAMA by McPheeters and colleagues, which pooled 118 clinical trials and 20,976 participants.
Its conclusion was direct: alongside psychosocial interventions, the findings support oral naltrexone at 50 mg per day and acamprosate as first-line pharmacotherapies for alcohol use disorder.
| Medication | Primary Effect | Best When Your Goal Is | Evidence Signal (JAMA 2023) |
| Oral naltrexone (50 mg/day) | Reduces cravings and heavy drinking | Cutting back without full abstinence | NNT 11 to prevent a return to heavy drinking; NNT 18 to prevent a return to any drinking |
| Acamprosate | Stabilizes brain chemistry after withdrawal | Maintaining abstinence post-withdrawal | NNT 11 to prevent a return to any drinking |
| Injectable naltrexone (Vivitrol) | Same as oral, with monthly dosing | Adherence is hard with daily pills | About 5 fewer drinking days per 30 days; low strength of evidence for preventing a return to drinking |
| Disulfiram (Antabuse) | Causes an unpleasant reaction if you drink | A strong deterrent with supervised dosing | Three trials showed no association with preventing a return to any drinking |
| Topiramate (off-label) | Reduces heavy drinking | First-line options are unsuitable or ineffective | Moderate strength of evidence for fewer drinking days |
| Gabapentin (off-label) | Reduces drinking, may help sleep | Co-occurring anxiety or insomnia | Low strength of evidence |
| Baclofen (off-label) | Reduces drinking | Liver disease limits other options | Low strength of evidence |
NNT means number needed to treat: how many people have to take the medication for one additional person to benefit. An NNT of 11 is considered good for a chronic condition.
Treat these figures as directional rather than precise, since several of the confidence intervals in the review were wide. If you are weighing the two first-line options, we break down how acamprosate and naltrexone differ in more detail.
For most people starting out, oral naltrexone and acamprosate. The 2023 JAMA review supports that answer directly, and it is why both appear as first-line options in clinical guidance.
Two findings deserve a plain reading:
Match the medication to your goal first, then work through dosing and interactions with your prescriber.
| Medication | Route | Typical Adult Dose | Frequency |
| Oral naltrexone | Oral tablet | 50 mg | Once daily |
| Naltrexone (Vivitrol) | Deep IM gluteal injection | 380 mg | Every 4 weeks |
| Acamprosate | Oral delayed-release tablet | 666 mg (two 333 mg tablets) | Three times daily |
| Disulfiram | Oral tablet | 250 mg maintenance (range 125 to 500 mg) | Once daily |
| Topiramate (off-label) | Oral tablet | Titrated to a maximum of 300 mg/day | Daily, divided |
| Gabapentin (off-label) | Oral capsule | Commonly 600 mg three times daily | Three times daily |
Acamprosate is cleared by the kidneys, so kidney function sets the dose. The label recommends starting at one 333 mg tablet three times daily for moderate renal impairment, defined as a creatinine clearance of 30 to 50 mL/min, and it is contraindicated when creatinine clearance is 30 mL/min or below.
Liver health shapes the naltrexone conversation instead. The American Psychiatric Association’s 2018 practice guideline recommends that naltrexone not be used by people who have acute hepatitis or hepatic failure.
For people with significant liver disease, acamprosate is often the more comfortable choice. Untreated hepatitis C is worth addressing in parallel, and baclofen has been studied specifically in people with cirrhosis.
Gabapentin and topiramate also need renal dose adjustment. Tell your prescriber about any kidney or liver diagnosis before the first prescription, not after.
Oral medications should be taken according to label guidance with respect to food. Injectable naltrexone is given in the gluteal muscle every four weeks, and adherence is reviewed at each follow-up visit.
Because insurance prior authorization for injectables can add days, our team confirms it before your first appointment rather than at the pharmacy counter.
Injectable formulations carry a higher list price than oral medications and more often require prior authorization or step therapy. Our team checks formulary tiers before prescribing and coordinates with your insurance to prevent coverage delays.
Porch Light Health accepts Medicaid and Medicare and works with major commercial insurers including Anthem Blue Cross Blue Shield, UnitedHealthcare, Humana, Cigna, and Kaiser Permanente.
We also offer a sliding fee program based on family size and income for people who are uninsured or paying out of pocket. Coverage for any specific medication depends on your plan and eligibility, so the fastest way to get a real answer is to ask us to check.
Every medication for alcohol use disorder carries specific safety considerations. Knowing what to watch for is part of safe treatment, not a reason to avoid it.
| Medication | Most Common Side Effects | Key Safety Check | Important Restriction |
| Naltrexone (oral or injectable) | Nausea, headache, fatigue | Liver history reviewed before starting | Contraindicated with current opioid use or opioid agonist therapy |
| Disulfiram | Drowsiness, metallic taste | Confirm 12+ hours alcohol-free before the first dose | Contraindicated with metronidazole, severe myocardial disease or coronary occlusion, and psychoses |
| Acamprosate | Diarrhea, drowsiness | Creatinine clearance before starting | Contraindicated if creatinine clearance is 30 mL/min or below |
| Topiramate (off-label) | Cognitive slowing, paresthesias, weight loss | Cognition and mood monitoring | Avoid in pregnancy; caution with glaucoma and kidney stones |
| Gabapentin (off-label) | Sedation, dizziness | Respiratory risk review; renal dosing | FDA warns of serious breathing problems when combined with opioids or other CNS depressants |
The gabapentin row matters for a lot of our patients.
In December 2019 the FDA warned that serious breathing difficulties may occur in people using gabapentin or pregabalin who have respiratory risk factors, including opioid pain medicines and other central nervous system depressants, along with conditions like COPD.
Older adults are at higher risk too. Anyone taking buprenorphine or methadone needs that conversation before gabapentin is added.
We cover what patients tend to notice first in our detailed write-up on naltrexone side effects.
The disulfiram-alcohol reaction can be genuinely dangerous, and it does not require a drink to trigger it. The label instructs patients to avoid alcohol in disguised forms, including sauces, vinegars, cough mixtures, aftershave lotions, and back rubs.
Worth checking before you start:
Sensitivity does not end with your last pill. The label notes that a reaction to alcohol may occur up to 14 days after taking disulfiram, so the same precautions apply for two weeks after stopping.
Naltrexone blocks opioid receptors, which creates two practical issues:
If you are stable on buprenorphine or methadone for opioid use disorder, the usual approach is to continue that therapy and use other strategies for drinking rather than switching to naltrexone.
Any transition between them is a supervised clinical decision, never a self-directed one.
One more thing patients rarely hear up front: if you need emergency surgery or acute pain control while on naltrexone, tell the treating team you are taking it, because standard opioid analgesia may not work as expected. Carrying a note in your wallet or a medical alert card is a reasonable precaution.
The liver warning is widely misreported, so here is the precise version.
Naltrexone no longer carries an FDA boxed warning for liver toxicity; that warning was removed when the prescribing information was revised in 2013.
The current label still includes a hepatotoxicity warning noting that cases of hepatitis and clinically significant liver dysfunction have been reported, and it directs that patients be warned of the risk and told to seek medical attention if they develop symptoms of acute hepatitis.
The current label does not require routine liver function testing. Whether liver testing is appropriate for you, and how often, is a clinical judgment your prescriber makes based on your history.
Starting medication for alcohol use disorder begins with three things:
You can find a clinic near you to start or continue care.
Our intake team reviews liver history and orders liver function tests where clinically indicated before naltrexone. Kidney function is checked before prescribing acamprosate, and hepatitis C screening is offered to patients with risk factors.
If baseline liver tests are abnormal, they are rechecked within one to two weeks of starting naltrexone. We also monitor adherence, side effects, and urine toxicology as clinically indicated.
A phone check during the first week assesses tolerance, followed by an in-person visit at one month and routine reviews every three months with labs as needed.
Before starting medication, our intake team confirms the items below as part of what to expect at your first visits:
Patients are counseled to avoid opioids while on naltrexone and to watch for jaundice, severe rash, or new suicidal thoughts, any of which warrant urgent evaluation.
If labs worsen, side effects become intolerable, or heavy drinking continues despite adherence, we either switch medications or step up the intensity of care.
Medication that helps you stop drinking and medication that gets you safely through withdrawal are two different things, and confusing them is common.
Withdrawal management is short-term and focused on symptoms in the first days after your last drink. Benzodiazepines, dosed against a standardized symptom scale, are the mainstay, often with thiamine and other vitamin supplementation.
None of the three FDA-approved maintenance medications treats withdrawal.
Stopping abruptly after heavy, sustained drinking can be dangerous. Seizures and delirium tremens are medical emergencies.
Risk climbs with a history of withdrawal seizures, prior DTs, older age, and co-occurring medical illness. If any of that describes you, talk to a clinician before you stop rather than after.
Many people can be managed safely without a hospital stay. Our ambulatory medically supervised withdrawal services support withdrawal on an outpatient basis, with clinical monitoring while you stay at home and keep your responsibilities.
Maintenance medication is usually started at the end of that process, or during it in the case of naltrexone.
Off-label medications can be useful when the FDA-approved options are not a good fit. Evidence supports modest benefit for some agents, and they tend to work best within a comprehensive treatment plan rather than as standalone solutions.
SSRIs and other antidepressants do not treat alcohol use disorder itself. They are appropriate when a co-occurring depressive or anxiety disorder needs treatment, but they should not be prescribed as a substitute for one of the medications above.
Our dual diagnosis care team handles both problems together rather than in sequence.
Any licensed prescriber can prescribe medication for alcohol use disorder. No special federal waiver or certification is required, unlike some medications used for opioid use disorder. Any of these can start you on naltrexone, acamprosate, or disulfiram:
The barrier is usually familiarity rather than authority, which is part of why so few people who could benefit are offered these medications. If your primary care provider has not raised the subject, you can raise it.
Medication for alcohol use disorder can be started and managed by video visit, which removes a lot of the friction for people who live far from a clinic or cannot take time off work.
Secure video visits pair with local lab draws, and our mobile nursing team handles injectables so the monthly shot is not the thing that stops you.
Picking a medication is a shared decision. Your treatment goal, medical history, prior medication response, and practical factors like access and dosing schedule all shape the choice.
If your goal is to reduce heavy drinking, naltrexone is often a strong first step. If abstinence is the target and your kidney function allows it, acamprosate is frequently the right fit.
The clearer you can be about what you actually want, the more tailored the plan can be.
Wanting to cut back rather than quit is a legitimate starting point, not a half-measure.
Be sure to mention any of the following, because each one can change which medications are safe and effective:
Our psychiatry providers and behavioral health team coordinate care when a co-occurring mental health diagnosis is part of the picture.
Bring this list to your appointment:
We talk through benefits, side effects, dosing schedule, and insurance coverage. Baseline labs and a pregnancy check are arranged, and an early follow-up is scheduled to confirm tolerance and adherence.
Some situations change the calculation enough to be worth naming.
Starting medication for alcohol use disorder usually follows the same general workflow, whether you are seen in-clinic or by telemedicine:
Careful documentation and early follow-up help us catch safety issues quickly and decide when specialty addiction care is the right next step.
You cannot start medication for another adult. You can do more than you might think.
Bringing up medication as a medical option, rather than as a referendum on willpower, lands very differently. Offering to sit in on the first appointment removes a real barrier, and handling the practical parts, like a ride or a pharmacy pickup, keeps momentum going.
One thing not to do: disulfiram must never be given to someone without their full knowledge. The label is explicit about it, and covert dosing is both dangerous and a betrayal of the trust the person will need to recover.
Pharmacotherapy for alcohol use disorder remains underused despite clear benefits, and the reasons are usually logistical rather than clinical. Community-delivered care lowers transportation and stigma barriers, and it puts treatment inside the life someone is already living.
Our network expands access through clinics, mobile medical units, and telemedicine across more than 60 points of care in Colorado and New Mexico.
You can find a nearby location or a virtual option by calling 866-839-8868. Treatment closer to home is treatment that is easier to keep.
Which medications are first-line for alcohol use disorder, and why?
Oral naltrexone and acamprosate. The 2023 JAMA systematic review of 118 trials supports both as first-line alongside psychosocial treatment: naltrexone reduces heavy drinking, acamprosate maintains abstinence once achieved. The right choice depends on your goal, your comorbidities, and whether daily or monthly dosing fits your life.
Can I drink alcohol while taking naltrexone?
Yes, and many people do while they are cutting back. Naltrexone does not make you sick if you drink, which separates it from disulfiram. It reduces alcohol’s rewarding effect, so drinking feels less satisfying and is easier to stop. Disulfiram is the opposite, and its reaction can be dangerous.
Is naltrexone addictive?
No. Naltrexone is an opioid antagonist, not an opioid. It does not produce euphoria, it is not habit-forming, and it does not cause physical withdrawal if you stop. Neither acamprosate nor disulfiram is habit-forming either.
Can I take naltrexone if I am on opioid pain medication or buprenorphine?
No. Naltrexone is contraindicated in people taking opioid analgesics or maintained on methadone or buprenorphine, and recent opioid use must be confirmed absent first. The label recommends an opioid-free interval of at least 7 to 10 days for short-acting opioids. If you are stable on agonist therapy, continue it.
How long before I see benefits, and can I stop once I feel better?
Many people notice fewer cravings within two to four weeks of starting naltrexone, and our guide to how long naltrexone takes to work breaks the timeline down. Acamprosate takes several weeks. Stopping early raises relapse risk, so medication is commonly continued at least six to 12 months after drinking stops.
Is there a cure for alcohol use disorder?
No. Alcohol use disorder is a chronic, treatable condition, and the disulfiram label says outright that the medication is not a cure. Medication plus counseling can substantially reduce drinking and support long stretches of stability, which is a more honest promise than a cure.
What labs do I need before starting naltrexone or acamprosate, and how often?
Liver history is reviewed before naltrexone, with liver function testing where clinically indicated, though the current label does not mandate routine testing. Kidney function is checked before acamprosate, which is contraindicated when creatinine clearance is 30 mL/min or below. A pregnancy test and opioid screen are standard.
Is the injectable naltrexone more effective than the oral version?
Not clearly. The injection improves adherence by replacing daily pills with a monthly visit, but the pooled evidence for preventing a return to any drinking is weaker than for oral naltrexone at 50 mg daily. Our comparison of Vivitrol and oral naltrexone walks through choosing between them.
Are anticonvulsants like topiramate or gabapentin safe and effective?
Both reduce heavy drinking and both are off-label. Topiramate has moderate-strength evidence but causes cognitive slowing and paresthesias, and is avoided in pregnancy. Gabapentin has low-strength evidence, misuse potential, and an FDA warning about breathing problems with opioids. The VA/DoD guideline puts topiramate first-line; the APA treats both as second-line.
What happens if you drink while taking disulfiram?
A disulfiram-alcohol reaction warrants medical attention. Mild reactions include flushing, headache, and nausea. Severe reactions can involve very low blood pressure, chest pain, or breathing difficulty and need emergency evaluation. Sensitivity can persist up to 14 days after the last dose, so the same precautions apply after stopping.
Does Ozempic or another GLP-1 medication treat alcohol use disorder?
Not as approved treatment. GLP-1 medications such as semaglutide are approved for diabetes and weight management, not alcohol use disorder. Early randomized trials in JAMA Psychiatry (2025) and The Lancet (2026) reported reductions in heavy drinking, but both were short and small. Bring it to your clinician rather than seeking one yourself.
How do clinicians overcome insurance and access barriers?
Coverage limits are addressed with accurate coding, peer-to-peer appeals, and generics where appropriate. For injectables, documenting a trial of oral therapy and medical necessity supports prior authorization. Telemedicine, local clinic partnerships, and patient navigators expand access, and our team helps with assistance programs and scheduling.
Whether you are asking about medication for alcohol use disorder for yourself or for someone you love, our team at Porch Light Health is here, not to judge, but to help.
A confidential call takes about five minutes and can answer what you are wondering about next steps, insurance, and what treatment actually looks like.
Call our team at 866-839-8868 to speak with someone today, or get connected with a Porch Light Health clinic to start with a location.
Same-day consultations are often available. We are here when you are ready.
